These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9467939)

  • 21. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
    Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A
    J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability.
    Gretarsdottir S; Thorlacius S; Valgardsdottir R; Gudlaugsdottir S; Sigurdsson S; Steinarsdottir M; Jonasson JG; Anamthawat-Jonsson K; Eyfjörd JE
    Cancer Res; 1998 Mar; 58(5):859-62. PubMed ID: 9500438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of BRCA2 gene in sporadic breast tumours.
    Bièche I; Noguès C; Lidereau R
    Oncogene; 1999 Sep; 18(37):5232-8. PubMed ID: 10498873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13.
    Collins N; McManus R; Wooster R; Mangion J; Seal S; Lakhani SR; Ormiston W; Daly PA; Ford D; Easton DF
    Oncogene; 1995 Apr; 10(8):1673-5. PubMed ID: 7731724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
    Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
    Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of heterozygosity at selective sites on chromosomes 13 and 17 in human breast carcinoma.
    Thorlacius S; Jonasdottir O; Eyfjord JE
    Anticancer Res; 1991; 11(4):1501-7. PubMed ID: 1746906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
    Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
    Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
    Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
    Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
    Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
    Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
    Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.
    Beghelli S; Pelosi G; Zamboni G; Falconi M; Iacono C; Bordi C; Scarpa A
    J Pathol; 1998 Sep; 186(1):41-50. PubMed ID: 9875139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
    Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
    Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene.
    Liscia DS; Morizio R; Venesio T; Palenzona C; Donadio M; Callahan R
    Br J Cancer; 1999 May; 80(5-6):821-6. PubMed ID: 10360661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
    Pääkkönen K; Sauramo S; Sarantaus L; Vahteristo P; Hartikainen A; Vehmanen P; Ignatius J; Ollikainen V; Kääriäinen H; Vauramo E; Nevanlinna H; Krahe R; Holli K; Kere J
    Genet Epidemiol; 2001 Feb; 20(2):239-46. PubMed ID: 11180449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.